# The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

> **NCT03178123** · PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 220 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody Toripalimab
- **BIOLOGICAL:** high-dose recombinant interferon a-2B

## Key facts

- **NCT ID:** NCT03178123
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-31
- **Primary completion:** 2022-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178123, "The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03178123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*